Finally, in a prospective trial carried out in Hubei, China the prophylactic administration of IFN by the nasal route combined with barrier measures was reported to lead to a zero incidence of COVID-19 among caregivers (Meng et al., 2020). This evidence concerns the gene IFNA1 and COVID-19.